ArticleOncogene2026
PTP4A3 dephosphorylates EGFR to promote metastasis and enhance sensitivity to lapatinib in hepatocellular carcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Protein tyrosine phosphatase type IVA 3 (PTP4A3) is implicated in the metastasis of hepatocellular carcinoma (HCC), yet its precise regulatory mechanisms remain elusive. This study aimed to identify the interacting substrates and underlying mechanisms of PTP4A3 to inform the optimization of PTP4A3-targeted therapies in HCC. Using the TurboID system and protein mass spectrometry, over 500 candidate substrates for PTP4A3 were identified. A direct interaction between PTP4A3 and epidermal growth factor receptor (EGFR) was also validated. Ti-IMAC protein phosphorylation mass spectrometry revealed that PTP4A3 dephosphorylates Thr693 of EGFR. This dephosphorylation event enhanced EGFR-ERBB2 heterodimerization, leading to increased RhoA-GTPase activation, cell motility, and cytoskeletal rearrangement. EGFR/ERBB2 inhibition effectively suppressed PTP4A3-driven metastasis both in vitro and in vivo. This study reveals a novel mechanism by which PTP4A3 promotes HCC metastasis via direct dephosphorylation of EGFR at Thr693. Lapatinib, an inhibitor of EGFR/ERBB2, effectively suppressed PTP4A3-driven HCC metastasis, offering a potential therapeutic strategy for HCC patients with high PTP4A3 expression. The regulatory mechanism of PTP4A3 regulating HCC cell metastasis. PTP4A3 overexpression promotes EGFR-ERBB2 heterodimer formation by dephosphorylating EGFR at Thr693, inhibiting its degradation. This sustained EGFR activation enhances HCC cell motility via RhoA-GTP signaling. Lapatinib, an EGFR/ERBB2 inhibitor, effectively counteracts the pro-migratory effects of PTP4A3.
Indexed as
Identifiers
42420588What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.